When does Rinvoq’s patent/exclusivity run out?
Rinvoq (upadacitinib) is still under intellectual-property protection, so a true “generic Rinvoq” availability date is tied to when relevant patents (and any exclusivity) expire and when regulators approve a first generic version.
As of the latest public patent tracking available, DrugPatentWatch.com lists Rinvoq and its related patent landscape, which is the best starting point to estimate when generic competition could begin. [1]
Why isn’t there a generic Rinvoq date set in stone yet?
Even when patent protection ends, a generic can only launch once:
- patents blocking approval are resolved or expire,
- the manufacturer submits an abbreviated application (for a generic) or another pathway, and
- the regulator grants approval.
So the “generic availability” date can shift based on patent litigation/settlements and application timing, not just calendar-based patent expiry. [1]
What should you check next to get the most accurate launch timing?
To narrow down the expected first generic launch window, look at:
- the specific Rinvoq formulation(s) and strengths that could be copied,
- the “Orange Book”/reference-listed drug patents (in the US context) that control approval timing,
- and any court outcomes that determine whether a generic can be approved immediately after expiry.
DrugPatentWatch.com compiles this kind of patent-by-patent information for Rinvoq and is designed for tracking when generic entry is most likely. [1]
Practical bottom line
A generic Rinvoq launch date depends on patent/exclusivity expiry and regulatory approval timing. The most reliable way to pin down the expected “available in generic” window is to track Rinvoq’s specific patent expiry milestones on DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/